Table 3.

Multivariable Logistic Regression Analysis of Breakthrough Infection for n = 505 Patients

Covariates	Odds Ratio (95% Confidence Interval)	P Value
Antibody response
Negative (<5 lU/mL)	1.053 (0.523–2.118)	0.884
Very low (5–44 lU/mL)	1.971 (0.757–5.132)	0.164
Low (45–204 IU/mL)	1.849 (0.75–4.504)	0.176
Medium (205–817 IU/mL)	2.447 (1.039–5.763)	0.040
High (>817 lU/mL)	ref.
Type of graft
Kidney	ref.
Liver	0.505 (0.218–1.172)	0.112
Heart	0.666 (0.277–1.601)	0.364
Lung	0.78 (0.305–2.017)	0.616
Vaccine sequence
BNT162b2–BNT162b2–mRNA-1273	ref.
mRNA-1273–mRNA-1273–mRNA-1273	0.608 (0.330–1.11)	0.110
BNT162b2–BNT162b2–BNT162b2	1.456 (0.643–3.300)	0.367
Age at first vaccine dose	0.969 (0.950–0.98)	0.003
Time from transplant to vaccine first dose	0.945 (0.904–0.988)	0.013
Female	1.083 (0.634–1.849)	0.770
Calcineurin inhibitors	0.777 (0.165–3.647)	0.750
Mycophenolate	1.335 (0.704–2.532)	0.375
Mammalian target of rapamycin inhibitors	0.755 (0.294–1.933)	0.558
Steroids	1.186 (0.599–2.350)	0.624
Comorbidities	0.969 (0.560–1.677)	0.913
Severe acute respiratory syndrome coronavirus 2 infection preceding vaccination	0.404 (0.037–4.388)	0.457
Constant	2.055 (0.249–16.959)	0.503

Abbreviation: mRNA, messenger RNA.